Flunisolide hydrofluoroalkane with integrated spacer for treating asthma: An updated review

Allergy and Asthma Proceedings

Volumn 36, Issue 2, 2015, Pages 105-115

  Berger, William E ^a   Tashkin, Donald P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; CHLOROFLUOROCARBON; CORTICOSTEROID; FLUNISOLIDE; FLUORINATED HYDROCARBON; ANTIINFLAMMATORY AGENT; FLUOCINOLONE ACETONIDE;

AEROSOL; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHMA; DRUG CLEARANCE; DRUG DELIVERY DEVICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; LUNG BIOPSY; MAXIMUM PLASMA CONCENTRATION; PARTICLE SIZE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; ANIMAL; CHILD; INHALATION SPACER; MEDICINAL CHEMISTRY; UNITED STATES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTHMA; CHEMISTRY, PHARMACEUTICAL; CHILD; CHLOROFLUOROCARBONS; FLUOCINOLONE ACETONIDE; HUMANS; INHALATION SPACERS; UNITED STATES;

EID: 84923831428     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2015.36.3835     Document Type: Article

References (62)

1. Blackwell DL, Lucas JW, and Clarke TC. Summary health statistics for U.S. adults: National Health Interview Survey 2012. National Center for Health Statistics. Vital Health Stat 10:1-161, 2014
2. Bloom B, Jones LI, and Freeman G. Summary health statistics for U.S. children: National Health Interview Survey 2012. National Center for Health Statistics. Vital Health Stat 10:1-81, 2013
3. National Ambulatory Medical Care Survey (NAMCS): 2010 Summary Tables. Available online at www.cdc.gov/nchs/ data/ahcd/NAMCS-30A-2010.pdf; accessed May 21, 2014
4. National Hospital Ambulatory Medical Care Survey (NHAMCS): 2010 Emergency Department Summary Tables. Available online at www.cdc.gov/nchs/data/ahcd/nhamcs100ed-2010.pdf; accessed May 21, 2014
5. National Hospital Ambulatory Medical Care Survey (NHAMCS): 2010 Outpatient Department Summary Tables. Available online at www.cdc.gov/nchs/data/ahcd/nhamcs100opd-2010.pdf; accessed May 21, 2014
6. Moorman JE, Akinbami LJ, Bailey CM, et al. National surveillance of asthma: United States 2001-2010. National Center for Health Statistics. Vital Health Stat 3:1-67, 2012
7. Murphy SL, Xu J, and Kochanek KD. Deaths: Final data for 2010. National Vital Statistics Report 61:1-117, 2013
8. Centers for Disease Control Vital Signs, 2011. Available online at www.cdc.gov/vitalsigns; accessed May 21, 2014
9. National Asthma Education and Prevention Program (NAEPP). Expert panel report 3: Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute, Bethesda, MD, 2007
10. Zeidler M, and Corren J. Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat Respir Med 3:35-44, 2004
11. Meda Pharmaceuticals, Inc. Aerospan(flunisolide) inhalation aerosol prescribing information. Somerset, NJ; Last revised August, 2013
12. Corren J, Nelson H, Greos LS, et al. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. Ann Allergy Asthma Immunol 87: 405-411, 2001
13. Corren J, and Tashkin DP. Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma. Clin Ther 25:776-798, 2003
14. Richards J, Hirst P, Pitcairn, et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med 4:197-208, 2001
15. Nolting A, Sista S, and Abramowitz W. Flunisolide HFA versus flunisolide CFC: Pharmacokinetic comparison in healthy volunteers. Biopharm Drug Dispos 22:373-382, 2001
16. Shafazand S, and Colice G. Flunisolide HFA for the treatment of asthma: An old friend reformulated. Expert Opin Pharmacother 5:1163-1173, 2004
17. Melani AS. Flunisolide for the treatment of asthma. Expert Rev Clin Pharmacol 7:251-258, 2014
18. Casale TB, Nelson HS, Corren J, and Newman K. Long-term safety of flunisolide hydrofluoroalkane metered-dose inhaler in adults and adolescents with asthma. Clin Drug Invest 21:755-764, 2001
19. Gillman SA, Anolik R, Schenkel E, and Newman K. One-year trial on safety and normal linear growth with flunisolide HFA in children with asthma. Clin Pediatr (Phila) 41:333-340, 2002
20. Bensch GW, Greos LS, Gawchik S, et al. Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: A randomized, double-blind, placebocontrolled trial. Ann Allergy Asthma Immunol 107:323-329, 2011
21. Meda Pharmaceuticals, Inc. Data on file. Somerset, NJ.
22. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: A randomised, double-blind trial. Lancet 361:1071-1076, 2003
23. Price JF, Russell G, Hindmarsh PC, et al. Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma. Pediatr Pulmonol 24: 178-186, 1997
24. Sharek PI, and Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: A meta-analysis. Pediatrics 106:E8, 2000
25. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 343:1054-1063, 2000
26. Kelly HW, Sternberg AL, Lescher R, et al.; CAMP Research Group. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 367:904-912, 2012
27. Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 28:1042-1050, 2006
28. Nolting A, and Abramowitz W. Multiple-dose proportionality study of flunisolide hydrofluoroalkane. Allergy Asthma Proc 23:311-318, 2002
29. Nolting A, Sista S, and Abramowitz W. Single-dose study to compare the pharmacokinetics of HFA flunisolide and CFC flunisolide. J Pharmaceu Sci 91:424-432, 2002
30. Mollmann H, Derendorf H, Barth J, et al. Pharmacokinetic/ pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. J Clin Pharmacol 37:893-903, 1997
31. Martin R. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol 109:S447-S460, 2002
32. Hamid Q. Pathogenesis of small airways in asthma. Respiration 84:4-11, 2012
33. van der Berge M, ten Hacken NH, van der Wiel E, and Postma DS. Treatment of the bronchial tree from beginning to end: Targeting small airway inflammation in asthma. Allergy 68:16-26, 2013
34. Hauber HP, Gotfried M, Newman K, et al. Effect of HFAflunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol 112:58-63, 2003
35. Newman SP. Deposition and effects of inhaled corticosteroids. Clin Pharmacokinet 42:529-544, 2003
36. Bergeron C, Hauber HP, Gotfried M, et al. Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: Effect of hydrofluoroalkane-flunisolide. J Allergy Clin Immunol 116:983-989, 2005
37. Benayoun L, Druilhe A, Dombret MC, et al. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 167:1360-1368, 2003
38. James A, and Carroll N. Airway smooth muscle in health and disease; methods of measurement and relation to function. Eur Respir J 15:782-789, 2000
39. Profita M, Gagliardo R, Di Giorgi R, et al. In vitro effects of flunisolide on MMP-9, TIMP-1, fibronectin, TGF-beta1 release and apoptosis in sputum cells freshly isolated from mild to moderate asthmatics. Allergy 59:927-932, 2004
40. Zeidler MR, Kleerup EC, Kim HJG, et al. Reduction in distal inflammation after treatment with extrafine HFA-flunisolide as compared with coarse CFC-flunisolide. Am J Respir Crit Care Med 181:A6645, 2010
41. Berger W. Aerosol devices and asthma therapy. Curr Drug Deliv 6:38-49, 2009
42. Newman SP. Principles of metered-dose inhaler design. Respir Care 50:1177-1190, 2005
43. Rubin BK, and Fink JB. Optimizing aerosol delivery by pressurized metered-dose inhalers. Respir Care 50:1191-1197, 2005
44. Newman SP, Clark AR, Talaee N, and Clarke SW. Pressurised aerosol deposition in the human lung with and without an "open" spacer device. Thorax 44:706-710, 1989
45. McFadden ER Jr. Improper patient techniques with metered dose inhalers: Clinical consequences and solutions to misuse. J Allergy Clin Immunol 96:278-286, 1995
46. Wilkes W, Fink J, and Dhand R. Selecting an accessory device with a metered-dose inhaler: Variable influence of accessory devices on fine particle dose, throat deposition, and drug delivery with asynchronous actuation from a metered-dose inhaler. J Aerosol Med 14:351-360, 2001
47. Guss D, Barash IA, and Castillo EM. Characteristics of spacer device use by patients with asthma and COPD. J Emerg Med 35:357-361, 2008
48. Sheth P, Bertsch MD, Knapp CL, and Myrdal PB. In vitro evaluation of nonconventional accessory devices for pressurized metered-dose inhalers. Ann Allergy Asthma Immunol 113: 55-62, 2014. (Available online at www.dx.doi.org/10.1016/ j.anal.2014.04.006.)
49. Haughney J, Price D, Barnes NC, et al. Choosing inhaler devices for people with asthma: Current knowledge and outstanding research needs. Respir Med 104:1237-1245, 2010
50. Dolovich MB, Ahrens RC, Hess DR, et al.; American College of Chest Physicians, American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: Evidence-based guidelines. Chest 127:335-371, 2005
51. Haughney J, Price D, Kaplan A, et al. Achieving asthma control in practice: Understanding the reasons for poor control. Respir Med 102:1681-1693, 2008
52. Newman SP. Spacer devices for metered dose inhalers. Clin Pharmacokinet 43:349-360, 2004
53. Dolovich MB, and Dhand R. Aerosol drug delivery: Developments in device design and clinical use. Lancet 377:1032-1045, 2011
54. Dhand R, Dolovich M, Chipps B, et al. The role of nebulized therapy in the management of COPD: Evidence and recommendations. COPD 9:58-72, 2012
55. Hagmolen of ten Have W, van de Berg NJ, Bindels PJ, et al. Assessment of inhalation technique in children in general practice: Increased risk of incorrect performance with new device. J Asthma 45:67-71, 2008
56. The Inhaler Error Steering Committee, Price D, Bosnic-Anticevich S, Briggs A, et al. Inhaler competence in asthma: Common errors, barriers to use, and recommended solutions. Respir Med 107:37-46, 2013
57. Crompton GK. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis Suppl 63:101-104, 1982
58. Rubin BK. What does it mean when a patient says, "my asthma medication is not working"? Chest 126:972-981, 2004
59. Giraud V, and Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 19:246-251, 2002
60. Global Initiative for Asthma (GINA). Guidelines and resources. Available online at www.ginasthma.com/GuidelinesResources.asp? l1-2&l2-0; accessed June 19, 2014
61. Melani AS, Bonavia M, Cilenti V, et al.; Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 105:930-938, 2011
62. Vella C, and Grech V. Assessment of use of spacer devices for inhaled drug delivery to asthmatic children. Pediatr Allergy Immunol 16:258-261, 2005